Axsome celebrates migraine PhIII win, shifting eyes toward a pair of Q4 submissions
One week after reporting a late-stage failure for its lead drug, Axsome is back with positive news: In the 302-person Phase III INTERCEPT trial, its experimental migraine drug hit both primary endpoints: Stopping migraine pain entirely and preventing pain from progressing beyond ”mild intensity.”
The trial win sets up a big fourth quarter for the 8-year-old company and keeps them on track to file for approval for the migraine drug, known as AXS-05. And despite the late-stage failure, they plan to file for approval on their lead depression drug, known as AXS-07, citing secondary endpoints and the high placebo rates that have long clouded depression trial results.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.